PRKAR1A, identified through a proteomic analysis, emerged as a promising cell surface-expressed biomarker capable of regulating cancer’s biological functions, EMT, and stemness through the ERK signaling pathway, consequently reducing the cytotoxic effects associated with resistance to anticancer agents. This evidence concerns the gene PRKAR1A and cancer.